ARA 290
Also known as: Cibinetide
At a Glance
ARA 290 (also called cibinetide) is an erythropoietin-derived peptide investigated for tissue-protective signaling and symptom/endpoint modulation in select disease contexts. Evidence is indication-specific and includes small early-phase clinical studies. [PMID: 32674280]
⚠️ Research Status: ARA 290 is not an approved medication. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
ARA 290 is commonly framed as engaging non-hematopoietic, tissue-protective signaling associated with erythropoietin biology; mechanistic specifics should be verified from primary sources for each indication.
Evidence Summary
Diabetic Macular Edema (Phase 2)
Low Confidence Observational ≤3 YearsA small Phase 2 study in diabetic macular edema reported no mean improvement on key endpoints over the study period, with possible signals in subsets and no serious safety reactions in this cohort. [PMID: 32674280]
Safety & Unknowns
- Safety and efficacy are indication-dependent; the accessible clinical evidence base is limited.
- Larger, controlled studies are needed to characterize benefit-risk.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |